Patents by Inventor Frank Mattner
Frank Mattner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9029327Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: GrantFiled: July 23, 2010Date of Patent: May 12, 2015Assignee: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Publication number: 20150093432Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating ?-amyloidoses including Alzheimer's disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).Type: ApplicationFiled: April 30, 2013Publication date: April 2, 2015Applicant: AFFIRIS AGInventors: Markus Mandler, Wolfgang Zauner, Frank Mattner, Walter Schmidt
-
Publication number: 20150093431Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating synucleinopathies, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).Type: ApplicationFiled: April 30, 2013Publication date: April 2, 2015Applicant: AFFIRIS AGInventors: Markus Mandler, Petra Gruber, Frank Mattner, Walter Schmidt
-
Patent number: 8900564Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.Type: GrantFiled: May 21, 2008Date of Patent: December 2, 2014Assignee: Valneva Austria GmbHInventors: Jörg Fritz, Frank Mattner, Wolfgang Zauner, Eszter Nagy, Michael Buschle
-
Publication number: 20140255435Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (SEQ?ID?NO:?1) (X1)m?(X2)n?(X3)o?X4?X5?H?P?X6 (Formula?I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicant: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Publication number: 20140242727Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.Type: ApplicationFiled: September 20, 2012Publication date: August 28, 2014Applicant: AFFIRIS AGInventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
-
Publication number: 20140234877Abstract: Disclosed is a method for detecting A?-specific antibodies in a biological sample comprising the following steps:—contacting the sample with A?-aggregates or with particles comprising A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and -detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS.Type: ApplicationFiled: September 20, 2012Publication date: August 21, 2014Applicant: AFFIRIS AGInventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
-
Publication number: 20140179900Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.Type: ApplicationFiled: November 21, 2013Publication date: June 26, 2014Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Patent number: 8618046Abstract: The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes FX8(F)oPX9HX10X11X12DX2X3X4X5X6X7 where X8 is G, A, F, Y or K, X9 is E, Y, A, Q, K or S, X10 is H, V, L, F or I, X11 is L, W, S, I, F or Y, X12 is V, T, F or I, X5 is S or Y, X6 is L, A or I, X7 is S, N or T, and o is 0 or 1.Type: GrantFiled: August 8, 2008Date of Patent: December 31, 2013Assignee: Affiris AGInventors: Sylvia Brunner, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Patent number: 8613931Abstract: The present invention relates to the use of mimotopes in the treatment of diseases associated with ?-amyloid formation and/or aggregation (?-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A?1-40/42, A?pE3-40/42, A?3-40/42 and A?11-40/42.Type: GrantFiled: June 12, 2009Date of Patent: December 24, 2013Assignee: Affiris AGInventors: Markus Mandler, Christian Gieffers, Frank Mattner, Andrea Dolischka, Oleksandr Otava
-
Publication number: 20130287807Abstract: The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (A?).Type: ApplicationFiled: February 19, 2013Publication date: October 31, 2013Inventors: Markus MANDLER, Frank Mattner, Walter Schmidt
-
Publication number: 20130230545Abstract: The present invention relates to the use of mimotopes in the treatment of diseases associated with ?-amyloid formation and/or aggregation (?-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A?1-40/42, A?pE3-40/42, A?3-40/42 and A?11-40/42.Type: ApplicationFiled: March 15, 2013Publication date: September 5, 2013Inventors: Markus MANDLER, Christian Gieffers, Frank Mattner, Andrea Dolischka, Oleksandr Otava
-
Publication number: 20130216565Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).Type: ApplicationFiled: December 21, 2011Publication date: August 22, 2013Applicant: Affiris AGInventors: Guenther Staffler, Christine Landlinger, Frank Mattner
-
Patent number: 8361476Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independantly one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.Type: GrantFiled: October 18, 2001Date of Patent: January 29, 2013Assignee: Intercell AGInventors: Jörg Fritz, Frank Mattner, Wolfgang Zauner, Eszter Nagy, Michael Buschle
-
Publication number: 20120269836Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: ApplicationFiled: July 23, 2010Publication date: October 25, 2012Applicant: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Patent number: 8277815Abstract: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.Type: GrantFiled: May 18, 2011Date of Patent: October 2, 2012Assignee: Intercell AGInventors: Michael Buschle, Julia-Kristina Fleitmann, Frank Mattner, Jack Melling
-
Publication number: 20110300169Abstract: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.Type: ApplicationFiled: May 18, 2011Publication date: December 8, 2011Applicant: INTERCELL AGInventors: JULIA-KRISTINA FLEITMANN, FRANK MATTNER, MICHAEL BUSCHLE, JACK MELLING
-
Publication number: 20110275556Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.Type: ApplicationFiled: August 8, 2008Publication date: November 10, 2011Applicant: AFFIRIS AGInventors: Sylvia Brunner, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Patent number: 8022180Abstract: The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A?42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A?42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.Type: GrantFiled: July 6, 2005Date of Patent: September 20, 2011Assignee: Affiris Forschungs-und Entwicklungs GmbHInventors: Frank Mattner, Walter Schmidt
-
Publication number: 20110201987Abstract: The invention relates to a method for preventing or treating Alzheimer's disease (AE). According to said method, a means for inducing a sequestration of amyloid ? (A?) into a plasma is administered to a person, and the person is treated by means of an apheresis device comprising a fixed carrier that can come into contact with the blood or plasma flow and comprises a receptor binding an amyloid-?-precurser-protein (APP), the APP being removed from the blood of the person by means of the apheresis device. The invention also relates to a set for carrying out said method.Type: ApplicationFiled: March 11, 2011Publication date: August 18, 2011Applicant: AFFIRIS Forschungs-und Entwicklungs GmbHInventors: Frank Mattner, Walter Schmidt